As of 2025-07-01, the EV/EBITDA ratio of Mersana Therapeutics Inc (MRSN) is 0.52. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRSN's latest enterprise value is -39.33 mil USD. MRSN's TTM EBITDA according to its financial statements is -75.33 mil USD. Dividing these 2 quantities gives us the above MRSN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.8x - 12.5x | 12.2x |
| Forward P/E multiples | 11.8x - 20.2x | 16.0x |
| Fair Price | (5.29) - (5.64) | (6.41) |
| Upside | -1996.4% - -2120.4% | -2399.2% |
| Date | EV/EBITDA |
| 2025-06-30 | 0.49 |
| 2025-06-27 | 0.50 |
| 2025-06-26 | 0.43 |
| 2025-06-25 | 0.38 |
| 2025-06-24 | 0.40 |
| 2025-06-23 | 0.40 |
| 2025-06-20 | 0.35 |
| 2025-06-18 | 0.37 |
| 2025-06-17 | 0.37 |
| 2025-06-16 | 0.32 |
| 2025-06-13 | 0.34 |
| 2025-06-12 | 0.35 |
| 2025-06-11 | 0.32 |
| 2025-06-10 | 0.26 |
| 2025-06-09 | 0.30 |
| 2025-06-06 | 0.31 |
| 2025-06-05 | 0.34 |
| 2025-06-04 | 0.34 |
| 2025-06-03 | 0.38 |
| 2025-06-02 | 0.33 |
| 2025-05-30 | 0.39 |
| 2025-05-29 | 0.38 |
| 2025-05-28 | 0.35 |
| 2025-05-27 | 0.36 |
| 2025-05-23 | 0.37 |
| 2025-05-22 | 0.30 |
| 2025-05-21 | 0.37 |
| 2025-05-20 | 0.30 |
| 2025-05-19 | 0.31 |
| 2025-05-16 | 0.40 |
| 2025-05-15 | 0.45 |
| 2025-05-14 | 0.32 |
| 2025-05-13 | 0.36 |
| 2025-05-12 | 0.36 |
| 2025-05-09 | 0.44 |
| 2025-05-08 | 0.41 |
| 2025-05-07 | 0.43 |
| 2025-05-06 | 0.45 |
| 2025-05-05 | 0.35 |
| 2025-05-02 | 0.28 |
| 2025-05-01 | 0.28 |
| 2025-04-30 | 0.21 |
| 2025-04-29 | 0.34 |
| 2025-04-28 | 0.31 |
| 2025-04-25 | 0.35 |
| 2025-04-24 | 0.35 |
| 2025-04-23 | 0.30 |
| 2025-04-22 | 0.33 |
| 2025-04-21 | 0.43 |
| 2025-04-17 | 0.37 |